Please assess the completion status of the following clinical trial:

Trial Title: Cholecalciferol and Flu Vaccine in Treating Healthy Participants

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy individuals seen at the Employee Health Clinic who will be eligible to receive influenza vaccine~* Willingness to comply with study expectations~* subject or legal representative must understand the investigational nature of this study and sign an Independent Ethics Committee/Institutional Review Board approved written informed consent form prior to receiving any study related procedure~* INTERVENTION COMPONENT ONLY:~* Willing to suspend use of any other vitamin D supplementation during the 3 month treatment interval; if currently using \> 2,000 IU/day of vitamin D supplementation, must suspend use 30 days prior to enrollment~Exclusion criteria:~-not RPCI employee

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 64 Years
- Healthy Volunteers: t

Study Arms:
- Arm I (400 IU cholecalciferol and vaccine therapy) (Type: EXPERIMENTAL): Patients receive low-dose cholecalciferol PO QD for 12 weeks, followed by the seasonal (2012-2013) trivalent influenza vaccine IM.
- Arm II (4,000 IU cholecalciferol and vaccine therapy) (Type: EXPERIMENTAL): Patients receive high-dose cholecalciferol PO QD for 12 weeks, followed by the seasonal (2012-2013) trivalent influenza vaccine IM.

Based on this trial design, predict the completion outcome and termination type (if applicable).